论文部分内容阅读
目的观察瑞舒伐他汀对轻中度高血压伴高脂血症患者炎性因子和踝臂指数的影响。方法将轻中度高血压伴高脂血症患者114例随机分为观察组和对照组,每组57例。对照组给予常规降压治疗,观察组在对照组的基础上给予瑞舒伐他汀治疗。治疗后比较2组患者各项血脂指标、超敏C反应蛋白(hs-CRP)、血压、踝臂指数(ABI)变化以及不良反应发生率。结果治疗前2组患者血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和hs-CRP比较差异无统计学意义(P>0.05),治疗后2组患者TC、TG、LDL-C和hs-CRP水平均降低,且观察组低于对照组,差异均有统计学意义(P<0.05)。治疗前2组患者的收缩压、舒张压和ABI比较差异均无统计学意义(P>0.05),治疗后2组患者的舒张压、收缩压、ABI均改善(P<0.05),但2组间舒张压和收缩压比较差异无统计学意义(P>0.05);治疗后观察组ABI高于对照组(P<0.05)。2组患者的不良反应发生率比较差异无统计学意义(P>0.05)。经过对症治疗以及间断性停药等措施后,2组不良反应均得到有效缓解。结论瑞舒伐他汀治疗高血压伴高脂血症疗效显著,能有效改善患者血脂和血管内皮功能,有效抑制患者的炎性反应和动脉粥样硬化进程,且不会明显增加患者的不良反应,值得临床广泛推广。
Objective To observe the effect of rosuvastatin on inflammatory factors and ankle brachial index in patients with mild to moderate hypertension and hyperlipidemia. Methods One hundred and fourteen patients with mild to moderate hypertension and hyperlipidemia were randomly divided into observation group and control group, 57 cases in each group. The control group was given conventional antihypertensive treatment, the observation group was given rosuvastatin on the basis of the control group. After treatment, the levels of blood lipid, hs-CRP, ABI and incidence of adverse reactions in the two groups were compared. Results There was no significant difference in serum total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) and hs-CRP between the two groups before treatment (P> 0.05) The levels of TC, TG, LDL-C and hs-CRP were all lower in the observation group than those in the control group, with statistical significance (P <0.05). There was no significant difference in systolic pressure, diastolic pressure and ABI between the two groups before treatment (P> 0.05). After treatment, diastolic blood pressure, systolic blood pressure and ABI were improved in both groups (P <0.05) There was no significant difference in diastolic pressure and systolic pressure between the two groups (P> 0.05). After treatment, the ABI in observation group was higher than that in control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). After symptomatic treatment and intermittent withdrawal and other measures, two groups of adverse reactions have been effectively alleviated. Conclusion Rosuvastatin treatment of hypertension with hyperlipidemia significant effect, can effectively improve the patient’s blood lipids and vascular endothelial function, effectively inhibiting the patient’s inflammatory response and atherosclerosis progression, and will not significantly increase the adverse reactions in patients, Worth widespread clinical.